Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA
Recently, the IND application of TollB-001 Tablets, a class 1.1 new drug for rheumatoid arthritis by Toll Biotech, has been officially approved by the FDA, allowing clinical trials to be carried out in the United States. This is another milestone after TollB-001 tablet of Toll Biotech was accepted by China CDE. It is also an important step in Toll Biotech's international commercialization and expansion of overseas markets. Shanghai Medicilon Inc. (Medicilon), as a partner of Toll Biotech, provided pharmaceutical research services , including raw materials and preparation, for TollB-001 tablets, which accelerated the research process. Class 1.1 new drug TollB-001 tablet Drugs for Autoimmune Diseases with a New Mechanism TollB-001 tablet is a class 1.1 small molecule new drug developed for rheumatoid arthritis launched by Toll Biotech. Preclinical studies have shown that its efficacy and safety are significantly superior to clinical first-line drugs. It...